Tirzepatide (Mounjaro, Zepbound) represents a breakthrough in type 2 diabetes and weight management as the first dual GIP/GLP-1 receptor agonist approved by the FDA
Once that foundation of understanding is in place, the decision about whether to move forward with the Playbook or Foundation becomes straightforward and low-risk
Even if you were previously tolerating the medication without problems, altering the dose, such as taking a half dose or splitting it, can trigger severe nausea, vomiting, or diarrhea
This baseline establishes your pre-combination values against which all future labs will be compared
We typically recommend that patients take Tirzepatide once a week, on the same day each week, at any time of the day, with or without food
Smith-Reed's sex life with her husband had ups and downs over their 17-year marriage not uncommon for a long-term relationship